Navigation Links
Efficacy Advantages and Long-Term Cost Savings Will Help Optimize Reimbursement in the EU5 for Type 2 Diabetes Agents
Date:8/26/2013

BURLINGTON, Mass., Aug. 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that as the health technology assessment bar rises sharply across the EU5 (France, Germany, Italy, Spain and the United Kingdom), interviewed payers seek robust efficacy advantages over the right comparators and clear demonstration of potential for downstream cost savings in exchange for optimal reimbursement of type 2 diabetes therapies. As type 2 diabetes becomes increasingly prevalent in Western markets, the cost of related complications and comorbidities weighs heavily on tightening EU5 healthcare budgets. Payers report that novel agents that delay disease progression and show positive weight loss and cardiovascular outcomes data, ideally with detailed pharmacoeconomic analyses, will secure favorable market access conditions long term.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The new European Physician and Payer Forum report entitled Market Access Challenges Facing Newly Launched and Emerging Type 2 Diabetes Agents in the EU5: Physician Prescribing Perspectives and Payer Insights finds that at least three-quarters of surveyed EU5 endocrinologists, diabetologists and general practitioners (GPs) believe that, despite market crowding, unmet need remains for the DPP-IV inhibitor drug class, while at least two-thirds think likewise for the GLP-1 receptor agonists. Key unmet needs highlighted for the DPP-IV inhibitors include better reduction in HbA1c, and confirmation of disease-modifying effect, while—in addition to injection-free admin
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
2. MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
3. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
4. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
5. Optimization of Comparative Efficacy Trials
6. JAMA Study Demonstrates Efficacy of Life Technologies Lung Cancer Test in Detecting Early Metastases, Supports Screening for Lung Cancer
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
9. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
10. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
11. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 2, 2015 Valencia Technologies Corporation (" ... patient with its radically small device for the treatment ... results in this randomized, double-blinded, controlled trial are compelling ... confidence that it will succeed in a large U.S. ... clinical results, Valencia has successfully ...
(Date:3/2/2015)... Following announcements from both Novartis and ... Inc. (NASDAQ:  ARRY) today announced the completion of ... Novartis.  Along with global ownership of both assets, ... million from Novartis. Ron Squarer, Chief ... the Novartis-GSK transaction, Array now owns both binimetinib ...
(Date:3/2/2015)... , March 2, 2015  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of a ... and cholesterol gallstones, today announced that Josh Blacher ... at the 27th Annual ROTH conference in ... 2015 at 2:30 PM Pacific Standard Time. A live ...
Breaking Medicine Technology:Valencia Technologies Implants its 48th Patient, Continues Equity Crowdfunding 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 2Array Announces Completion Of Binimetinib And Encorafenib Transactions 3Array Announces Completion Of Binimetinib And Encorafenib Transactions 4Array Announces Completion Of Binimetinib And Encorafenib Transactions 5Galmed Pharmaceuticals to Present at the 27th Annual ROTH Conference 2
(Date:3/2/2015)... Dinner preparation and meal planning have ... of DinnerDork , a company that specializes ... thousands of busy customers. The company recently responded ... offer a total of 6 diverse meal plan ... recipes and comfort foods; Paleo Palette, which caters ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Regulatory ... focused on quality, regulatory and technical consulting, announces ... Chief Operating Officer. , Before joining RCA, ... leading R&D teams in all aspects of developing ... positions at Covidien (Medtronic), Regulatory Compliance Associates Inc., ...
(Date:3/2/2015)... March 02, 2015 What are the ... physicians request references? When are interviews scheduled, how can ... opportunities?, Both training and practicing physicians who are looking ... questions and more at the PracticeLink Physician Career Advancement ... drop-in Job Fair is from 5:30 to 8:30 p.m. ...
(Date:3/2/2015)... ProvidaStaff has announced today that ... division to EDU Healthcare to reflect better ... systems and students nationwide. , “ProvidaStaff has always been ... the country,” said Angela M. Lewis, President of ProvidaStaff. ... and the introduction of EDU Healthcare better aligns our ...
(Date:3/2/2015)... Secura Consultants announced today the ... Protective Insurance Group of Birmingham, AL (First Protective). ... affiliated advisors to access the enhanced disability income ... delivers. , Secura Consultants, based in ... design and implementation of insured income protection programs. ...
Breaking Medicine News(10 mins):Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 3Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Secura Consultants and First Protective Insurance Group Announce Strategic Relationship 2
... ... Rules Technology without Spending a Dime , ... Redwood City, CA (PRWEB) October 19, 2009 -- Corticon Technologies, ... another breakthrough in the Business Rules industry with the immediate availability of Corticon RulesWorld™. ...
... the U.S. Department of Justice issued formal guidelines for federal ... of marijuana for medical purposes. A memo from Deputy Attorney ... new position of the department. , The memo provided in ... priorities should not focus federal resources in your ...
... 19 Solomon Nathaniel of Sterling Heights, Mich., pleaded ... participating in a conspiracy to defraud the Medicare program, ... Criminal Division, U.S. Attorney Terrence Berg of the Eastern ... of the Department of Health & Human Services (HHS). ...
... blood flow is blocked protects tissue, animal study finds, ... research, scientists have shown in animal studies that providing ... damage. , But it,s not a simple matter. Success ... on when 100 percent oxygen is given. , ...
... when compared to kids without disorder , MONDAY, Oct. ... differences in blood mercury levels between children who are ... spectrum disorders. , The findings, appearing online Oct. 19 ... quell some of the debate surrounding mercury and autism. ...
... D.C., October 19, 2009 With chronic diseases on ... to improve care and outcomes for these often complex ... announced a new initiative funded with a grant from ... allow pediatricians across the country to pilot a series ...
Cached Medicine News:Health News:Corticon Launches RuleWorld Community and Free Business Rules Software 2Health News:Corticon Launches RuleWorld Community and Free Business Rules Software 3Health News:Corticon Launches RuleWorld Community and Free Business Rules Software 4Health News:Detroit-Area Physical Therapist Pleads Guilty in Medicare Fraud Scheme 2Health News:Timing of Oxygen After a Stroke May Matter 2Health News:Mercury Levels Not Abnormal in Autistic Children 2Health News:Mercury Levels Not Abnormal in Autistic Children 3Health News:Pediatricians put proven treatment strategies to work against childhood asthma 2
... has been providing accurate, reliable PT/INR results where ... care. , The CoaguChek System is the instrument ... monitoring on Coumadin (warfarin sodium) therapy. The CoaguChek ... from a fingerstick drop (10ul) of whole blood ...
The QuickScreen Pro Multi Drug Screening Test is a rapid, self-timing, qualitative immunoassay for,the detection of drugs of abuse in urine....
... ADC drugs of abuse tests are highly accurate ... SAMHSA recommended cut-off as confirmed by GC/MS testing. ... more specific alternative method (such as GC/MS) must ... result. Professional judgment should be applied to any ...
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
Medicine Products: